Fig. 5.

Covariate “dashboard” for an ulcerative colitis patient receiving infliximab. This plot shows how three key covariates known to affect the pharmacokinetics of infliximab change over time. Lack of efficacy may result in weight loss as seen in the first plot. The dose given may not be adequate leading to more severe disease and increased clearance of infliximab. Improvement in the disease may be reflected in the serum albumin returning to the normal range and the potential to reduce the dose of infliximab. The development of ADA may require an increase in the dose of infliximab or a change of medication